Your browser doesn't support javascript.
loading
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.
Liu, Mingtao; Gan, Hui; Liang, Zhiman; Liu, Li; Liu, Qiwen; Mai, Yiyin; Chen, Huihuang; Lei, Baoying; Yu, Shangwei; Chen, Huihui; Zheng, Peiyan; Sun, Baoqing.
Afiliación
  • Liu M; National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
  • Gan H; National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
  • Liang Z; National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
  • Liu L; Guangzhou Medical University, Guangzhou, China.
  • Liu Q; Guangzhou Medical University, Guangzhou, China.
  • Mai Y; Guangzhou Medical University, Guangzhou, China.
  • Chen H; Guangzhou Medical University, Guangzhou, China.
  • Lei B; Guangzhou Medical University, Guangzhou, China.
  • Yu S; Guangzhou Medical University, Guangzhou, China.
  • Chen H; Guangzhou Medical University, Guangzhou, China.
  • Zheng P; National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
  • Sun B; National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Front Microbiol ; 14: 1122868, 2023.
Article en En | MEDLINE | ID: mdl-37007494
COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and treatment of acute infectious diseases. Hundreds of SARS-CoV-2 neutralizing antibody studies are currently underway around the world, with some already in clinical applications. The development of SARS-CoV-2 neutralizing antibody opens up a new therapeutic option for COVID-19. We intend to review our current knowledge about antibodies targeting various regions (i.e., RBD regions, non-RBD regions, host cell targets, and cross-neutralizing antibodies), as well as the current scientific evidence for neutralizing-antibody-based treatments based on convalescent plasma therapy, intravenous immunoglobulin, monoclonal antibodies, and recombinant drugs. The functional evaluation of antibodies (i.e., in vitro or in vivo assays) is also discussed. Finally, some current issues in the field of neutralizing-antibody-based therapies are highlighted.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza